AMN Healthcare Services (AMN) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue was $688 million, down 19% year-over-year but exceeded expectations due to core results and discrete items; net income was $7 million, a significant decrease from $53 million in Q3 2023.

• Adjusted EBITDA was $74 million, above consensus but down 45% year-over-year; adjusted EPS was $0.61, compared to $1.97 in the prior year.

• Market stabilization is emerging, with travel nurse demand up 60% from April lows but still 35% below 2019 levels; language services and locum tenens showed growth, aided by the MSDR acquisition.

• Technology investments, including the WorkWise suite, have improved client engagement and competitive positioning, with top clients now using an average of 10 solutions.

• For the nine months ended September 30, 2024, revenue was $2.25 billion, down 24% year-over-year, with nurse and allied solutions comprising 60% of total revenue.

Financial highlights

• Gross margin was 31.0%, down 290 basis points year-over-year and flat sequentially; operating margin was 3.2%, down from 10.2% in Q3 2023.

• Adjusted EBITDA margin was 10.7%, down from 15.7% a year ago; net income was $7 million, down 87% year-over-year.

• Adjusted EPS was $0.61, compared to $1.97 in the prior year and $0.98 in the prior quarter; GAAP EPS was $0.18.

• Operating cash flow was $67 million in Q3; capital expenditures were $19 million; year-to-date debt repayment totaled $175 million.

• Cash and cash equivalents at quarter end were $31 million; total debt outstanding was $1.135 billion.

Outlook and guidance

• Q4 2024 revenue guidance is $685–$705 million, down 14–16% year-over-year; gross margin expected at 29.3–29.8%; adjusted EBITDA margin guidance is 9.2–9.7%.

• Nurse and Allied Solutions revenue outlook is 4% higher sequentially but expected to decline 21–24% year-over-year; other segments expected to be 5% below consensus.

• $45 million of Nurse and Allied revenue in Q4 is non-recurring, mainly from labor disruption, positively impacting gross margin by ~60 basis points.

• International nurse business headwinds from visa retrogression expected to taper in Q2 2025, with growth resuming by year-end 2025.

• Annual effective tax rate for 2024 is estimated at 24%.